Search
CELL BANK Website

Back Back
RCB1960 : HuCCT1  update : 2018/08/01
CommentHuman bile duct carcinoma. This cell line produces carbohydrate antigen 19/9 in serum-free medium. TKG0389 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsBasically, there is no restriction regarding academic use.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Obinata, Masuo
Originator Miyagiwa, M. (Okayama Univ.)
Year of deposit 2004
Original cell TKG0389
Animal human < Mammals
Genus Homo
Species sapiens
Age at sampling 56 years
Tissue bile duct, ascites meta
Case history bile duct carcinoma.
Metastastatic ability Yes
Metastatsd tissue asites
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0389)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 2
User's Publication 35


To topTop
Reference
3279  Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium  In Vitro Cell Dev Biol Anim  1989  25:503-510  PubMed ID: 2544546
5058  Matsuzaki K, Yoshitake Y, Miyagiwa M, Minemura M, Tanaka M, Sasaki H, Nishikawa K.  Production of basic fibroblast growth factor-like factor by cultured human cholangiocellular carcinoma cells.  Jpn J Cancer Res  1990  81(4):345-54  PubMed ID: 2163997

To topTop
User's Publication
7120  Agarinis C, Orsini V, Megel P, Abraham Y, Yang H, Mickanin C, Myer V, Bouwmeester T, Tchorz JS, Parker CN.  Activation of Yap-Directed Transcription by Knockdown of Conserved Cellular Functions.  J Biomol Screen  2015  21:269-76  PubMed ID: 26637552
7424  Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao AC, Zhao MH, Yang YB, Yang J.  High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.  World J. Gastroenterol.  2015  21:3256-65  PubMed ID: 25805932
7429  Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.  DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.  PLoS ONE  2015  10:e0120545  PubMed ID: 25799509
7767  Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.  Br. J. Cancer  2011  105:131-8  PubMed ID: 21673683
7898  Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S, Shimada M.  Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.  J. Med. Invest.  2011  58:106-9  PubMed ID: 21372494
7971  Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.  Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.  Cancer Sci.  2011  102:1045-51  PubMed ID: 21272158
9516  Samatiwat P, Takeda K, Satarug S, Ohba K, Kukongviriyapan V, Shibahara S.  Induction of MITF expression in human cholangiocarcinoma cells and hepatocellular carcinoma cells by cyclopamine, an inhibitor of the Hedgehog signaling.  Biochem. Biophys. Res. Commun.  2016  470:144-9  PubMed ID: 26773496
9668  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.  Src as a Therapeutic Target in Biliary Tract Cancer.  Mol. Cancer Ther.  2016  15:1515-24  PubMed ID: 27196758
10114  Edeline J, Coulouarn C, Crouzet L, Pracht M, Lepareur N, Clément B, Garin E.  Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.  J Vasc Interv Radiol  2015  26:1874-78.e2  PubMed ID: 26596183
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612
10312  Račkauskas R, Zhou D, Ūselis S, Strupas K, Herr I, Schemmer P.  Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti-apoptotic proteins.  Oncol. Rep.  2017  37:3660-3666  PubMed ID: 28498473
10363  Li P, Zhang L, Yang M, Qi M, Jin X, Han B.  Cul4B is a novel prognostic marker in cholangiocarcinoma.  Oncol Lett  2017  14:1265-1274  PubMed ID: 28808481
10461  Nooron N, Ohba K, Takeda K, Shibahara S, Chiabchalard A.  Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma.  Tohoku J. Exp. Med.  2017  242:291-302  PubMed ID: 28794318
10684  Kawashita Y, Morine Y, Saito Y, Takasu C, Ikemoto T, Iwahashi S, Teraoku H, Yoshikawa M, Imura S, Yagi T, Shimada M.  Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas.  J. Gastroenterol. Hepatol.  2018    PubMed ID: 29278438
10740  Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C.  A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma.  Hepatol Commun  2018  2:254-269  PubMed ID: 29507901
10759  Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549
11330  Komatsu N, Kajiya M, Motoike S, Takewaki M, Horikoshi S, Iwata T, Ouhara K, Takeda K, Matsuda S, Fujita T, Kurihara H.  Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.  Stem Cell Res Ther  2018    PubMed ID: 30526677
11345  Kim J, Kim H, Lee JC, Kim JW, Paik WH, Lee SH, Hwang JH, Ryu JK, Kim YT.  Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.  PLoS ONE  2018    PubMed ID: 30557411
11443  Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.  Invest New Drugs  2019    PubMed ID: 30778887
11459  Farley AM, Braxton DR, Li J, Trounson K, Sakar-Dey S, Nayer B, Ikeda T, Lau KX, Hardikar W, Hasegawa K, Pera MF.  Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma.  Sci Rep  2019    PubMed ID: 30814526
11476  Wei K, Li M, Zöller M, Wang M, Mehrabi A, Hoffmann K.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.  Cell Death Dis  2019    PubMed ID: 30850583
4244  Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.  Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.  Cancer Res Treat  2018    PubMed ID: 30514066
4245  Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.  Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.  Cancer Res Treat  2018    PubMed ID: 30282449
4339  Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M.  FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1.  Cancer Sci.  2018    PubMed ID: 30302867
4347  Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS.  Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.  Mar Drugs  2018    PubMed ID: 30563284
4486  Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.  Hepatology  2018  68(3):949-963  PubMed ID: 29278425
5430  Li C, Imai M, Yamasaki M, Hasegawa S, Takahashi N.  Effects of Pre- and Post-Administration of Vitamin A on the Growth of Refractory Cancers in Xenograft Mice.  Biol Pharm Bull  2017  40(4):486-494  PubMed ID: 28100867
3727  Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM  K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Mol Oncol  2017  11(9):1130-1142  PubMed ID: 28544747
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123
3736  Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.  Mol Cancer Ther.  2015  14(9):1985-93  PubMed ID: 26141945
3737  Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.  Cells  2019  8(9)  PubMed ID: 31484399
5767  Ito M, Sun S, Fukuhara T, Suzuki R, Tamai M, Yamauchi T, Nakashima K, Tagawa Y, Okazaki S, Matsuura Y, Wakita T, Suzuki T.  Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.  Oncotarget  2017  8(33):53899-53915  PubMed ID: 28903311
3923  Yoshitsugu OHNUKI, Takumi KONDO, Hiroshi KUROSAWA  ROCK INHIBITOR Y-27632 USED DURING CELL AGGREGATE FORMATION ADVERSELY AFFECTS THE EARLY CARDIAC DIFFERENTIATION OF HUMAN iPS CELLS  Tiss Cult Res Commun  2017  36:21–29 
6235  Li C, Imai M, Matsuura T, Hasegawa S, Yamasaki M, Takahashi N.  Inhibitory Effects of Retinol Are Greater than Retinoic Acid on the Growth and Adhesion of Human Refractory Cancer Cells.  Biol Pharm Bull  2016  39(4):636-40  PubMed ID: 2682241
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309



Back Back Return Top Page